Venetoclax-Ibrutinib Combinations as First-Line Therapy in Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials with GRADE Approach
Objective: Chronic lymphocytic leukemia (CLL) treatment has shifted from chemoimmunotherapy to targeted agents. Venetoclax and ibrutinib, which act through complementary mechanisms, have shown promise in achieving deep remissions. Their combination may enhance efficacy, but pooled evidence from rand...
محفوظ في:
| المؤلفون الرئيسيون: | , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Erzincan Binali Yıldırım University School of Medicine
2026-01-01
|
| سلاسل: | Archives of Basic and Clinical Research |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://abcresearch.net/articles/venetoclax-ibrutinib-combinations-as-first-line-therapy-in-chronic-lymphocytic-leukemia-a-meta-analysis-of-randomized-controlled-trials-with-grade-approach/doi/ABCR.2025.25386 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|